Even as the AIDS Drug Assistance Program (ADAP) crisis continues to grow (7,745 people are on waiting lists), Gilead Sciences has raised prices of its HIV meds, change.org reports. The cost of Atripla went up by 5.1 percent, while Truvada and Emtriva increased by 7.9 percent. Although Gilead is maintaining a price freeze for drugs going toward ADAP, the price increase can further stress the overburdened health care system including Medicare, Medicaid and private insurance companies.

To read the change.org article, click here.